Costs of intermittent versus continuous antiretroviral therapy in patients with controlled HIV infection: A substudy of the ANRS 106 window trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 4, 2008, Pages 416-421

  Charreau, Isabelle ^a   Jeanblanc, Grégoire ^b   Tangre, Philippe ^a   Boyer, Laurence ^c   Saouzanet, Marine ^a   Marchou, Bruno ^d   Molina, Jean Michel ^e   Aboulker, Jean Pierre ^a   Durand Zaleski, Isabelle ^b  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CHU NANCY BRABOIS   (France)

^d CHU PURPAN   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

Clinical trial; Cost; Economics; HIV infection; Treatment interruption

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG INTERMITTENT THERAPY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OPEN STUDY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SCREENING; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS;

EID: 57649129196     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818a657c     Document Type: Article

References (15)

1. Ananworanich J, Gayet-Ageron A, Le Braz M, et al, and the Staccato Study Group, the Swiss HIV Cohort Study. CDA-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368:459-465.
2. Danel C, Moh R, Anzian A, et al, for the Trivacan ANRS 1269 trial group. CD4-guided structured treatment antiretroviral strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367:1981-1989.
3. The Strategies for Management of antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
4. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis. 2003;188:388-396.
5. Alexander TH, Ortiz GM, Wellons MF, et al. Changes in CD4+ T-cell differentiation phenotypes during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2003;34:475-481.
6. Florence E, Garcia F, Plana M, et al. Long-term clinical follow-up, without antiretroviral therapy, of patients chronic HIV-1 infection with good virological response to structured treatment interruption. Clin Infect Dis. 2004;39:568-574.
7. 3. J Acquir Immune Defic Syndr. 2004;36:791-799.
8. Pai NP, Tulsky JP, Lawrence J, et al. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev. 2005;(4). CD005482. DOI: 10.1002/14651858.
9. Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chrome HIV type 1 infection. Clin Infect Dis. 2005;40:594-600.
10. Nuesch R, Ananworanich J, Sirivichayakul S, et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis. 2005;40:728-734.
11. Marchou B, Tangre P, Charreau I, et al, and the ANRS 106 Study Team. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS. 2007;21:457-466.
12. Drummond MF, O'Brien BJ, Stoddard GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, England: Oxford University Press; 1998:11.
13. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d'experts. Paris, France: Mé decinSciences Flammarion; 2004. ISBN: 2-257-10198-7. Tableau 4-V, Antirétroviraux en pharmacie de ville: prix moyen d'un traitement mensuel:54.
14. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6:171-177.
15. Hellinger FJ. Economic models of antiretroviral therapy: searching for the optimal strategy. Pharmacoeconomics. 2006;27:631-642.